Cancer Biology Program

癌症生物学项目

• 批准号: 10493586
• 负责人: KRISTI L NEUFELD
• 金额: $ 2.93万
• 依托单位: UNIVERSITY OF KANSAS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-07-11 至 2027-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10493586
• 关键词: Affect; Animal Model; Basic Science; Behavior; Biochemical; Biochemistry; Biological; Biological Markers; Bladder; Breast; Cancer Biology; Cancer Center; Cancer Center Support Grant; Catchment Area; Cell Proliferation; Cell Survival; Cells; Cellular biology; Cessation of life; Child; Clinical; Collaborations; Communities; DNA Repair; Development; Discipline; Disease; Distant; Fostering; Funding; Genes; Genetic; Genotoxic Stress; Goals; Hematologic Neoplasms; Hematopoietic System; Institutes; Institution; International; Invaded; Journals; Kansas; Kidney; Leadership; Liver; Malignant - descriptor; Malignant Neoplasms; Malignant neoplasm of gastrointestinal tract; Medical Research; Medical center; Methods; Molecular; NCI-Designated Cancer Center; Neoplasm Metastasis; Normal Cell; Organ; Outcome; Pancreas; Paper; Pathway interactions; Peer Review; Prevention strategy; Process; Publications; Publishing; Quality of life; Regulation; Research; Research Personnel; Signal Pathway; Signal Transduction; Strategic Planning; Therapeutic; Tissues; Tobacco-Related Carcinoma; Translating; Translational Research; Tumor Cell Biology; Tumor Stem Cells; United States National Institutes of Health; Universities; base; bench to bedside; biochemical model; cancer cell; cancer prevention; cancer therapy; cancer type; cell behavior; cell growth; cellular targeting; clinical development; cohesion; diagnostic strategy; experience; gastrointestinal; improved; interdisciplinary collaboration; meetings; member; multidisciplinary; neoplastic cell; novel; novel strategies; preclinical development; programs; recruit; response; stem cell biology; stem cell therapy; symposium; therapy development; therapy resistant; translational research program; tumor; tumor growth; tumor initiation; tumor microenvironment; tumor progression

CANCER BIOLOGY: ABSTRACT The Cancer Biology (CB) program represents basic science initiatives of The University of Kansas Cancer Center (KUCC), unified by member utilization of molecular, biochemical, and model organism and cell-based approaches to study the aberrant behavior of cancer cells. The CB scientific goal is to support KUCC’s strategic plan by discerning the molecular mechanisms that define normal and neoplastic cell growth to identify and characterize cells, molecules, pathways, and processes that are involved in tumor growth and progression, which can serve as useful biomarkers or as new cellular targets for cancer prevention and therapeutics, particularly in tumors important to the KUCC’s catchment area. To accomplish this, CB aims to catalyze collaborations that promote basic discoveries that can be translated from bench-to-bedside. CB has 46 full and 14 associate members representing four campuses: the University of Kansas Medical Center (KUMC) (67%), University of Kansas – Lawrence (KU-L) (10%), Children’s Mercy (CM) (5%), and Stowers Institute for Medical Research (Stowers) (18%). In 2020, CB garnered over $9M in cancer-related, peer-reviewed funding of which $1.2M was from NCI and $6.9M was from other institutes at NIH. From 2016- 2020, members published 880 cancer-relevant, peer-reviewed papers. Of these publications, 13% were in high-impact journals (JIF >10) and the average impact factor for all 880 publications is 6.1. Since renewing the CCSG in 2017, CB program cohesion and integration have increased, with 21% of the publications during the funding cycle resulting from inter-programmatic interactions (up from 20% in 2016) and 29% from intra- programmatic interactions (up from 21% in 2016). CB members are well-integrated into the national and international scientific community as evident by over half of the publications (51%) including authors from other institutions and 23% including authors from other NCI-designated cancer centers. CB is jointly led by Kristi Neufeld (KU-L), Linheng Li (Stowers), Sufi Thomas (KUMC), and Tomoo Iwakuma (CM), who bring complementary scientific expertise in cell biology, stem cell biology, biochemistry, translational research, leadership experience, and diverse institutional representation. Shrikant Anant is Associate Director for Basic Science. CB leadership employs a variety of mechanisms to foster intra- and inter-programmatic collaborations, including research retreats, seminars, research symposia, and targeted pilot funding. CB has taken advantage of historical institutional strengths in catchment area priorities, GI, and hematologic cancers, with recruitment strengthening our research on breast and tobacco-related cancers. CB members have expertise that can be organized into four discipline-based themes: 1) cancer metastasis and tumor microenvironment; 2) DNA damage/repair and regulation; 3) stem cell biology; and 4) cell signaling pathways.

癌症生物学：摘要 癌症生物学（CB）计划代表了堪萨斯癌症大学的基础科学计划 中心（KUCC），由分子，生物化学和模式生物和细胞为基础的成员利用统一 研究癌细胞异常行为的方法。CB的科学目标是支持KUCC的 通过辨别定义正常和肿瘤细胞生长的分子机制， 并表征参与肿瘤生长和进展的细胞、分子、途径和过程， 其可以作为有用的生物标记物或作为癌症预防和治疗的新细胞靶点， 特别是在KUCC集水区重要的肿瘤中。为了实现这一目标，CB旨在催化 这些合作促进了可以从实验室到临床的基本发现。 CB有46个正式成员和14个准成员，代表四个校区：堪萨斯医科大学 中心（KUMC）（67%），堪萨斯-劳伦斯大学（KU-L）（10%），儿童慈善（CM）（5%），和 Stowers医学研究所（Stowers Institute for Medical Research，18%）。2020年，CB在癌症相关的， 同行评审的资金，其中120万美元来自NCI，690万美元来自NIH的其他研究所。从2016年开始- 2020年，成员发表了880篇与癌症相关的同行评审论文。在这些出版物中，13%是在 高影响力期刊（JIF >10），所有880篇出版物的平均影响因子为6.1。自从更新了 CCSG在2017年，CB计划的凝聚力和整合力有所增加，21%的出版物在2017年， 资金周期来自项目间互动（2016年为20%），29%来自项目内互动。 程序化互动（高于2016年的21%）。CB成员很好地融入了国家和 国际科学界，超过一半的出版物（51%）包括来自其他国家的作者 23%的作者来自其他NCI指定的癌症中心。 CB由Kristi Neufeld（KU-L）、Linheng Li（Stowers）、Sufi托马斯（KUMC）和Tomoo Iwakuma共同领导 (CM)，他们在细胞生物学、干细胞生物学、生物化学、翻译 研究，领导经验和多样化的机构代表性。Shrikant Anant是副主任 基础科学能力建设领导层采用各种机制，促进方案内和方案间的 合作，包括研究务虚会，研讨会，研究座谈会，并有针对性的试点资金。CB有 利用了集水区优先事项、GI和血液学癌症方面的历史机构优势， 招募人员加强了我们对乳腺癌和烟草相关癌症的研究。CB成员有 专业知识，可以组织成四个学科为基础的主题：1）癌症转移和肿瘤 微环境; 2）DNA损伤/修复和调节; 3）干细胞生物学;和4）细胞信号传导途径。